Literature DB >> 2741180

Cholestyramine as an antidote against paracetamol-induced hepato- and nephrotoxicity in the rat.

C P Siegers1, W Möller-Hartmann.   

Abstract

Besides hepatotoxicity, paracetamol may exert nephrotoxic effects in experimental animals and man. The present study in rats shows that cholestyramine given 4 and 24 h after paracetamol provided protection against both hepato- and nephrotoxicity; this was evidenced by reduced increments in plasma enzyme activities (SDH, GPT), indicating liver damage, and diminished retention of plasma and creatinine, indicating renal failure. The recovery of paracetamol and its conjugates in urine was markedly reduced by cholestyramine at 24-48 h after treatment. The protective effects of cholestyramine are explained by adsorption of paracetamol and conjugates in the intestine undergoing biliary excretion and enterohepatic circulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2741180     DOI: 10.1016/0378-4274(89)90073-8

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  4 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Acetaminophen nephrotoxicity in male Wistar rats.

Authors:  L Trumper; G Girardi; M M Elías
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

3.  Tubular effects of acetaminophen in the isolated perfused rat kidney.

Authors:  L Trumper; L A Monasterolo; E Ochoa; M M Elias
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

4.  Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.

Authors:  Nicholas Moore; Stéphanie Duret; Adeline Grolleau; Régis Lassalle; Vanessa Barbet; Mai Duong; Nicolas Thurin; Cécile Droz-Perroteau; Sinem Ezgi Gulmez
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.